Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | WRN | Q14191 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | ENPP2 | Q13822 | 8/20 | 0.34 |
| ▸ | LPAR6 | P43657 | 3/20 | 0.33 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.33 |
| ▸ | LPAR4 | Q99677 | 3/20 | 0.33 |
| ▸ | LPAR5 | Q9H1C0 | 3/20 | 0.33 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.33 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.33 |
| ▸ | MGAM | O43451 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SI | P14410 | 1/20 | 0.33 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6276297 | 0.83 | MGAM (0.46) | MAPTENPP2LPAR6LPAR1LPAR4 | |
| SCHEMBL11720069 | 0.83 | TSHR (0.43) | ALDH1A1BLMMAPTENPP2LPAR6 | |
| SCHEMBL783993 | 0.82 | ALDH1A1 (0.46) | ALDH1A1MAPTENPP2LPAR6LPAR1 | |
| SCHEMBL1849409 | 0.81 | L3MBTL1 (0.33) | MGAMGAASIMGAM2 | |
| SCHEMBL12514827 | 0.81 | ALDH1A1 (0.35) | ALDH1A1GAA | |
| SCHEMBL3164875 | 0.81 | MAPT (0.34) | MAPTENPP2LPAR6LPAR1LPAR4 | |
| SCHEMBL1849412 | 0.80 | — | — | |
| SCHEMBL445120 | 0.79 | NAAA (0.39) | NAAAALDH1A1CYP1A2HPGDCYP2C19 | |
| SCHEMBL10918523 | 0.79 | TSHR (0.48) | ALDH1A1MAPTENPP2LPAR6LPAR1 | |
| SCHEMBL5663644 | 0.79 | NAAA (0.39) | NAAAALDH1A1CYP1A2HPGDCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1461041-A4 | PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANTIVIRAL NUCLEOSIDES | PHARMASSET LTD (BB) | 2006-03-29 | — | — | EP | claimed |
| EP-1461041-A2 | PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANTIVIRAL NUCLEOSIDES | Pharmasset Ltd. (BB) | 2004-09-29 | — | — | EP | claimed |
| US-20030162992-A1 | Reacting a 2,2-dialkoxyethyl halide with an appropriate carboxylate compound to obtain acetal compound; hydrolyzing the acetal to form the alpha -acyloxyacetaldehyde | PHARMASSET, INC. | 2003-08-28 | — | — | US | claimed |
| WO-2003051298-A2 | PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANTIVIRAL NUCLEOSIDES | PHARMASSET LTD. (BB) | 2003-06-26 | — | — | WO | claimed |
| US-8524691-B2 | Phosphonated rifamycins and uses thereof for the prevention and treatment of bone and joint infections | THE MEDICINES COMPANY (US) | 2013-09-03 | — | — | US | disclosed |
| US-20120070730-A1 | NONAQUEOUS ELECTROLYTE AND NONAQUEOUS ELECTROLYTE BATTERY | SONY CORPORATION (JP) | 2012-03-22 | — | — | US | disclosed |
| EP-1461041-A4 | PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANTIVIRAL NUCLEOSIDES | PHARMASSET LTD (BB) | 2006-03-29 | — | — | EP | disclosed |
| EP-1461041-A2 | PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANTIVIRAL NUCLEOSIDES | Pharmasset Ltd. (BB) | 2004-09-29 | — | — | EP | disclosed |
| US-20030162992-A1 | Reacting a 2,2-dialkoxyethyl halide with an appropriate carboxylate compound to obtain acetal compound; hydrolyzing the acetal to form the alpha -acyloxyacetaldehyde | PHARMASSET, INC. | 2003-08-28 | — | — | US | disclosed |
| WO-2003051298-A2 | PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANTIVIRAL NUCLEOSIDES | PHARMASSET LTD. (BB) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162992-A1 | Reacting a 2,2-dialkoxyethyl halide with an appropriate carboxylate compound to obtain acetal compound; hydrolyzing the acetal to form the alpha -acyloxyacetaldehyde | DERA, DPYD, DHPS | NAAA 75/4885ALDH1A1 14/4885CYP1A2 592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.